A fast-dissolving cariprazine hydrochloride orodispersible film preparation and preparation method thereof
Calcium hydrochloride is solved by using carcium hydrochloride of specific particle size and component ratio in the oral-soluble film preparation of carcium hydrochloride, combined with hydroxypropyl cellulose and hydroxypropyl cellulose or polyoxyethylene film forming materials The problems of slow onset of lirazine oral preparations and instable dissolution have achieved rapid dissolution and high mechanical properties under different pH media, which is suitable for rapid onset and easy medication in patients with schizophrenia.
Patent Information
- Application Number
- CN202411195676.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-29
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2044-08-29
AI Technical Summary
The existing oral preparations of carriparazine hydrochloride are slow onset, have low bioavailability, and have unstable gravel and disintegration speed. They are especially at high risk for patients with renal insufficiency and show unstable under different pH media. dissolution behavior.
Use 1%-10% carylaprazine hydrochloride as the active ingredient, combine 20%-80% hydroxypropylmethylcellulose and hydroxypropylcellulose or polyoxyethylene film forming materials, 5%-50% disintegrant and 2%-27% plasticizer, prepare a D90 cariprazine hydrochloride oral dissolving film preparation with a particle size of 40μm-95μm. Through specific component ratios and preparation methods, ensure rapid dissolution and high mechanical properties under different pH media. performance.
It realizes the effect of rapid dissolution of carylazine hydrochloride under different pH media, reduces the sense of gravel, improves bioavailability and mechanical properties, avoids the risk of nephrotoxicity of cyclodextrin, and is suitable for rapid onset of schizophrenia patients. And easy to take medicine.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of medicines, and in particular relates to a fast-dissolving cariprazine hydrochloride orodispersible film preparation and a preparation method thereof. Background Art
[0002] Cariprazine hydrochloride is mainly used to treat schizophrenia and bipolar mania. Cariprazine hydrochloride is a dopamine D2 / D3 receptor partial agonist that preferentially binds to the D3 receptor and has a lower incidence of extrapyramidal side effects compared to traditional psychotropic drugs that act on the D2 receptor alone.
[0003] Existing cariprazine capsules must first disintegrate in the stomach before they can begin to release drugs, resulting in slow onset and low bioavailability; patients with mental illnesses have poor treatment compliance and are prone to refusing treatment and vomiting drugs, and such drugs that need to be swallowed have the disadvantage of treatment compliance. Therefore, it is necessary to provide a cariprazine hydrochloride drug with fast dissolution, high solubility, and physical strength properties that meet the requirements.
[0004] Chinese invention patent CN107970217A discloses a cariprazine orally disintegrating tablet and a preparation method thereof. The patent uses ordinary tableting technology to prepare cariprazine into orally disintegrating tablets, which disintegrate rapidly and dissolve quickly. However, the drug prepared by this method still has a strong sense of grit when taken by patients, and the disintegration rate of the drug varies greatly. It is difficult to maintain a balance between tablet hardness and disintegration time during the tableting process.
[0005] Chinese invention patent CN115400099A discloses a cariprazine hydrochloride oral dissolving film composition, its preparation method and application, wherein the oral dissolving film composition comprises an active ingredient, a film-forming material and a plasticizer, wherein the active ingredient is selected from a mixture of one or more of cariprazine, a pharmaceutically acceptable salt of cariprazine and its inclusion compound. In the invention, cariprazine hydrochloride is included and prepared into an oral dissolving film using cyclodextrin. Since cyclodextrin may accumulate and crystallize in renal tubular epithelial cells after administration, causing cell necrosis and affecting renal function, the oral dissolving film is at a higher risk for patients with renal insufficiency; and the invention uses a cyclodextrin inclusion compound of cariprazine hydrochloride, which has an effect on the dissolution behavior of the product and further affects the onset speed of the drug; in addition, the particle size of the active ingredient cariprazine hydrochloride used is D90≤30μm, and the medicament prepared under this particle size exhibits unstable dissolution behavior in media with different pH values.
[0006] In view of this, it is necessary to further study the composition of the cariprazine hydrochloride orodispersible film preparation, the particle size of the main drug, etc., and develop a cariprazine hydrochloride orodispersible film preparation with a short dissolution time, rapid dissolution in media with different pH values, and high mechanical properties. Summary of the invention
[0007] The present invention aims to solve the problems existing in the prior art and provides a fast-dissolving cariprazine hydrochloride orodispersible film preparation and a preparation method thereof. The cariprazine hydrochloride orodispersible film preparation can achieve a very fast dissolution effect in dissolution media with different pH values, thereby providing a fast-acting and easy-to-take cariprazine hydrochloride oral preparation for schizophrenia patients.
[0008] To achieve the above purpose, the technical solution adopted by the present invention is as follows:
[0009] On the one hand, the present invention provides a fast-dissolving cariprazine hydrochloride orodispersible film preparation, which comprises the following components by mass fraction: 1%-10% active ingredient, 20%-80% film-forming material, 5%-50% disintegrant, 2%-27% plasticizer and 0.3%-3% other auxiliary ingredients;
[0010] The active ingredient is cariprazine hydrochloride, with a particle size range of D90 = 40 μm-95 μm;
[0011] The film-forming material is a mixture of hydroxypropyl methylcellulose and hydroxypropyl cellulose; or the film-forming material is polyoxyethylene;
[0012] The disintegrant is selected from one or more of mannitol, lactose, and sodium chloride;
[0013] The plasticizer is selected from one or more of polyethylene glycol 400, glycerol, propylene glycol, silicone oil, polypropylene glycol, hexylene glycol, and water.
[0014] Preferably, the cariprazine hydrochloride has a particle size range of D90=42 μm-94 μm.
[0015] Further preferably, the cariprazine hydrochloride has a particle size range of D90 = 42 μm-94 μm; the particle size range includes any range, real number and endpoint value within the numerical range, for example but not limited to 42 μm-94 μm, 42 μm-61.05 μm, 60 μm-80 μm, 73 μm-94 μm, 61.05 μm-93.47 μm; within the particle size range described in the present invention, the prepared cariprazine hydrochloride orosoluble film preparation can achieve the technical effect of the present invention without significant difference.
[0016] Preferably, the cariprazine hydrochloride orodispersible film preparation comprises the following components, calculated by mass fraction: 1.38%-8.09% active ingredient, 25.45%-79.76% film-forming material, 5.07%-46.18% disintegrant, 2.25%-20.59% plasticizer and 0.65%-2.21% other auxiliary ingredients.
[0017] Further preferably, the cariprazine hydrochloride orodispersible film preparation comprises the following components, calculated by mass: 8.09% active ingredient, 49.62% film-forming material, 27.59% disintegrant, 13.05% plasticizer and 1.65% other auxiliary ingredients.
[0018] Preferably, the cariprazine hydrochloride orodispersible film preparation comprises the following components, calculated by mass fraction: 2.90%-3.25% active ingredient, 71.14%-79.76% film-forming material, 5.07%-11.09% disintegrant, 5.24%-18.68% plasticizer and 0.66%-2.21% other auxiliary ingredients.
[0019] Preferably, the film-forming material is a mixture of hypromellose and hydroxypropyl cellulose.
[0020] More preferably, in the mixture of hypromellose and hydroxypropyl cellulose, the mass ratio of hypromellose to hydroxypropyl cellulose is 1:0.8-1.2.
[0021] Most preferably, the mass ratio of hypromellose to hydroxypropyl cellulose is 1:1.
[0022] Preferably, the disintegrant is mannitol.
[0023] Preferably, the plasticizer is selected from one or two of polyethylene glycol, propylene glycol and glycerol.
[0024] Preferably, the other auxiliary ingredients include: flavoring agents, coloring agents and pH adjusters.
[0025] Further preferably, the flavoring agent is selected from one or more of aspartame, sucralose, fructose, sucrose, steviol glycosides, glycyrrhizin, xylitol, acesulfame potassium, neotame, flavors, spices, menthol, saccharin, and saccharin sodium.
[0026] More preferably, the flavoring agent is selected from one or both of sucralose and xylitol.
[0027] Further preferably, the colorant is selected from one or more of titanium dioxide, yellow iron oxide, red iron oxide, black iron oxide, pigments, and lakes.
[0028] More preferably, the colorant is titanium dioxide.
[0029] Further preferably, the pH adjuster is an acidic pH adjuster or an alkaline pH adjuster;
[0030] The acidic regulator is selected from one or more of hydrochloric acid, citric acid, fumaric acid, adipic acid, malic acid, acetic acid, oleic acid, linoleic acid, succinic acid, and tartaric acid; the alkaline regulator is selected from one or more of sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, calcium oxide, magnesium oxide, calcium hydrogen phosphate, disodium hydrogen phosphate, and magnesium hydrogen phosphate.
[0031] More preferably, the pH adjuster is sodium hydroxide.
[0032] On the other hand, the present invention provides a method for preparing the above-mentioned cariprazine hydrochloride orodispersible film preparation:
[0033] When the film-forming material is a mixture of hydroxypropyl cellulose and hydroxypropyl methyl cellulose, the preparation method comprises the steps of:
[0034] (1) dissolving hydroxypropyl cellulose in water at 80°C-100°C to obtain a hydroxypropyl cellulose solution;
[0035] (2) stirring and dispersing the hydroxypropyl cellulose solution, active ingredient, disintegrant, plasticizer, hydroxypropyl methylcellulose, and other auxiliary ingredients to uniformly prepare a glue solution, coating, and drying to obtain a cariprazine hydrochloride orodispersible film preparation;
[0036] When the film-forming material is polyoxyethylene, the preparation method comprises the steps of:
[0037] The active ingredient, film-forming material, disintegrant, plasticizer and other auxiliary ingredients are dispersed and stirred evenly in water to form a glue solution, which is then coated and dried to obtain a cariprazine hydrochloride orodispersible film preparation.
[0038] Preferably, in step (1), the temperature of the water is 80°C-90°C.
[0039] Further preferably, in step (1), the temperature of the water is 85°C.
[0040] Preferably, in step (2), the stirring and dispersing is uniformly performed at room temperature.
[0041] Preferably, in step (2), the non-aqueous component in the glue solution accounts for 25%-45%.
[0042] Preferably, when the film-forming material is polyethylene oxide, the proportion of non-aqueous components in the glue solution is 25%-45%.
[0043] Compared with the prior art, the present invention has the following beneficial effects:
[0044] 1. The present invention does not use cyclodextrin with nephrotoxicity risk as a pharmaceutical excipient. By selecting components such as hydroxypropyl methylcellulose, hydroxypropyl cellulose, mannitol, polyethylene glycol, etc. to prepare the cariprazine hydrochloride oral dissolving film preparation, the obtained cariprazine hydrochloride oral dissolving film preparation can achieve the effect of rapid dissolution in dissolution media with different pH values, with short dissolution time, high tensile strength and high elongation. The cariprazine hydrochloride oral dissolving film preparation of the present invention has high dissolution performance and high mechanical properties.
[0045] 2. The present invention uses cariprazine hydrochloride with a specific particle size as the main drug to prepare a cariprazine hydrochloride orodispersible film preparation having high solubility in dissolution media of different pH values. The present invention achieves dissolution stability of the preparation by controlling the particle size. DETAILED DESCRIPTION
[0046] The following non-limiting examples can enable those skilled in the art to more fully understand the present invention, but do not limit the present invention in any way. The following content is merely an exemplary description of the scope of the present invention, and those skilled in the art can make various changes and modifications to the present invention based on the disclosed content, which should also fall within the scope of the present invention.
[0047] When the embodiments give numerical ranges, it should be understood that, unless otherwise specified in the present invention, both endpoints of each numerical range and any numerical value between the two endpoints can be selected. Unless otherwise defined, all technical and scientific terms used in the present invention have the same meanings as those generally understood by those of ordinary skill in the art to which the present invention belongs.
[0048] The present invention is further described below by way of specific examples. Unless otherwise specified, the various chemical reagents used in the examples of the present invention are obtained through conventional commercial channels.
[0049] In the following examples, the hydroxypropyl methylcellulose was purchased from Taian Ruitai Cellulose Co., Ltd. with a product number of 2303-079; the hydroxypropyl cellulose was purchased from Taian Ruitai Cellulose Co., Ltd. with a product number of 231226; the polyoxyethylene was purchased from Specialty Products US, LLC with a product number of D682LAKPI3; and the polyethylene glycol 400 was purchased from Jiangxi Yipsheng Pharmaceutical Co., Ltd. with a product number of 20240201. Products from different manufacturers have no significant effect on the effect.
[0050] "N / A" or " / " in the following examples means that the component is not used, or the value does not exist, or is not included in the composition ratio.
[0051] Example 1
[0052] A fast-dissolving cariprazine hydrochloride orodispersible film preparation, the components and dosage ratios of which are shown in Table 1:
[0053] Table 1
[0054]
[0055] The preparation method of cariprazine hydrochloride orodispersible film preparation is as follows:
[0056] (1) dissolving hydroxypropyl cellulose in purified water at 85° C. to obtain a hydroxypropyl cellulose solution;
[0057] (2) At room temperature, hydroxypropyl cellulose solution, cariprazine hydrochloride (API), mannitol (disintegrant), polyethylene glycol 400 (plasticizer), hydroxypropyl methylcellulose, sucralose, xylitol, titanium dioxide and sodium hydroxide are stirred and dispersed uniformly to prepare a gel solution, which is then defoamed, coated and dried to obtain a cariprazine hydrochloride orodispersible film preparation.
[0058] Example 2
[0059] A fast-dissolving cariprazine hydrochloride orodispersible film preparation, the components and dosage ratios of which are shown in Table 2. The preparation method of the cariprazine hydrochloride orodispersible film preparation is the same as that of Example 1.
[0060] Table 2
[0061]
[0062] Example 3-Example 4
[0063] A fast-dissolving cariprazine hydrochloride orodispersible film preparation (specification 1.5 mg), the components and dosage ratios of which are shown in Table 3:
[0064] Table 3
[0065]
[0066] The preparation method of the cariprazine hydrochloride orodispersible film preparation of Example 3 is as follows:
[0067] The preparation method of cariprazine hydrochloride orodispersible film preparation is as follows:
[0068] At room temperature, cariprazine hydrochloride, polyoxyethylene, mannitol, polyethylene glycol 400, propylene glycol, sucralose, xylitol, titanium dioxide, sodium hydroxide and water are stirred and dispersed uniformly to prepare a glue solution; after defoaming, coating and drying, a cariprazine hydrochloride orodispersible film preparation is obtained.
[0069] The preparation method of the cariprazine hydrochloride orodispersible film preparation of Example 4 is the same as that of Example 1.
[0070] Example 5-Example 6
[0071] A fast-dissolving cariprazine hydrochloride orodispersible film preparation (specification 1.5 mg), the components and dosage ratios of which are shown in Table 4. The preparation method of the cariprazine hydrochloride orodispersible film preparation is the same as that of Example 1.
[0072] Table 4
[0073]
[0074] Example 7-Example 8
[0075] A fast-dissolving cariprazine hydrochloride orodispersible film preparation (specification 1.5 mg), the components and dosage ratios of which are shown in Table 5. The preparation method of the cariprazine hydrochloride orodispersible film preparation is the same as that of Example 1.
[0076] Table 5
[0077]
[0078] Example 9-Example 10
[0079] A fast-dissolving cariprazine hydrochloride orodispersible film preparation (specification 1.5 mg), the components and dosage ratios of which are shown in Table 6. The preparation method of the cariprazine hydrochloride orodispersible film preparation is the same as that of Example 1.
[0080] Table 6
[0081]
[0082] Example 11-Example 12
[0083] A fast-dissolving cariprazine hydrochloride orodispersible film preparation (specification 1.5 mg), the components and dosage ratios of which are shown in Table 7. The preparation method of the cariprazine hydrochloride orodispersible film preparation is the same as that of Example 1.
[0084] Table 7
[0085]
[0086] Example 13-Example 16
[0087] A fast-dissolving cariprazine hydrochloride orodispersible film preparation (specification 1.5 mg), which is different from Example 1 in that the particle size (D90) of cariprazine hydrochloride is different, as shown in Table 8. The preparation method of the cariprazine hydrochloride orodispersible film preparation is the same as that of Example 1.
[0088] Comparative Example 1
[0089] A fast-dissolving cariprazine hydrochloride orodispersible film preparation (specification 1.5 mg), which is different from Example 1 in that the particle size (D90) of cariprazine hydrochloride is different, as shown in Table 8. The preparation method of the cariprazine hydrochloride orodispersible film preparation is the same as that of Example 1.
[0090] Table 8
[0091]
[0092] Comparative Example 2
[0093] The difference from Example 1 is that hypromellose is replaced by gelatin.
[0094] Comparative Example 3
[0095] The difference from Example 1 is that polyethylene glycol 400 is replaced by polyethylene glycol 600.
[0096] Comparative Example 4
[0097] In this comparative example, the cariprazine hydrochloride orodispersible film preparation was prepared according to the scheme of Example A5 described in the Chinese invention patent publication number CN115400099A.
[0098] Test 1 Physical properties investigation
[0099] 1. Melting time detection
[0100] Detection method: Place the cariprazine hydrochloride orodispersible film preparation of each example and comparative example in a culture dish containing 20 mL of purified water at a temperature of 37±0.5°C, and record the time when the sample is completely dissolved, which is the disintegration time.
[0101] 2. Tensile strength test
[0102] Testing method: Tensile strength is also called ultimate strength, which refers to the maximum force used to break the oral film.
[0103] Use intelligent electronic tensile testing machine for testing.
[0104] Tensile strength calculation formula: Tensile strength = applied stress / cross-sectional area.
[0105] 3. Elongation test
[0106] Test method: Elongation refers to the ratio of the increased length when the film is stretched by external force and breaks to the original length.
[0107] Use intelligent electronic tensile testing machine for testing.
[0108] The formula for calculating tensile strength is: elongation = increase in length / original length × 100%.
[0109] The dissolution time, tensile strength and elongation test results of the cariprazine hydrochloride orodispersible film preparations prepared in the examples and comparative examples are shown in Table 9.
[0110] Table 9
[0111]
[0112] As can be seen from Table 9, in the cariprazine hydrochloride oral dissolving film preparation of the present invention, the physical properties meet the requirements within the range of 1%-10% of the active ingredient. The disintegration slows down with the increase in the amount of film-forming material, and the tensile strength is enhanced. The proportion of film-forming material is within the range of 20%-80%, and the physical properties of the obtained sample meet the requirements. The amount of plasticizer increases, the tensile strength of the oral dissolving film preparation is enhanced, the disintegration slows down, and the proportion of plasticizer is within the range of 2%-25%, which meets the requirements. The type of disintegrant directly affects the disintegration, tensile strength and elongation of the film, and the type of plasticizer also has a direct impact on the physical properties.
[0113] In addition, different specifications of cariprazine hydrochloride orodispersible film preparations exhibit different physical properties. The physical properties of different specifications of cariprazine hydrochloride orodispersible film preparations prepared by the prescription of the present invention all meet the requirements.
[0114] Experiment 2: Dissolution behavior investigation
[0115] The dissolution behavior test was carried out according to the first method (basket method) of the 2020 edition of the "Chinese Pharmacopoeia". The specific test conditions are shown in Table 10.
[0116] Table 10
[0117]
[0118] The control preparation of the orodispersible film was Vraylar cariprazine hydrochloride oral preparation developed by Gedeon Richter USA, Inc., with batch number 1209286.
[0119] The cariprazine hydrochloride orodispersible film preparations prepared in the examples and comparative examples were tested for dissolution behavior in different dissolution media, and their dissolution rates (%) at 15 min were tested. The dissolution test results are shown in Table 11.
[0120] Table 11
[0121]
[0122] It can be seen from the dissolution results in Table 11 that the cariprazine hydrochloride orodispersible film preparations prepared in the embodiments of the present invention can meet the technical effect of very rapid dissolution, and the dissolution rate is above 85% within 15 minutes. Comparative Example 1 When the particle size D90 of cariprazine hydrochloride is changed, the solubility of the prepared cariprazine hydrochloride orodispersible film preparation in each dissolution medium is significantly reduced, and the technical effect of rapid dissolution cannot be achieved.
[0123] After using gelatin as the film-forming material in Comparative Example 2, the dissolution was significantly slower. In Comparative Example 3, using PEG 600, only the pH=1.2 medium basically met the very fast dissolution requirement (15min cumulative dissolution ≥85%), and the dissolution was still slow in the pH=4.5, pH=5.0 and pH=6.8 media. Comparative Example 4 failed to achieve very fast dissolution behavior in any medium.
[0124] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions of the technical solution of the present invention by ordinary technicians in this field do not deviate from the essence and scope of the technical solution of the present invention.
Claims
1. A fast-dissolving cariprazine hydrochloride orodispersible film preparation, It is characterized in that According to the mass fraction, the components include: 1.38%-8.09% active ingredient, 25.45%-79.76% film-forming material, 5.07%-46.18% disintegrant, 2.25%-20.59% plasticizer and 0.65%-2.21% other auxiliary ingredients; The film-forming material is a mixture of hydroxypropyl methylcellulose and hydroxypropyl cellulose, with a mass ratio of 1:0.8-1.2; or the film-forming material is polyoxyethylene; The active ingredient is cariprazine hydrochloride, with a particle size range of D90 = 40 μm-95 μm; The disintegrant is selected from one or more of mannitol, lactose, and sodium chloride; The plasticizer is selected from one or more of polyethylene glycol 400, glycerol and propylene glycol.
2. The cariprazine hydrochloride orodispersible film preparation according to claim 1, It is characterized in that Calculated by mass, the components include: 2.90%-3.25% active ingredient, 71.14%-79.76% film-forming material, 5.07%-11.09% disintegrant, 5.24%-18.68% plasticizer and 0.66%-2.21% other auxiliary ingredients.
3. The cariprazine hydrochloride orodispersible film preparation according to claim 1, It is characterized in that Calculated by mass, the components include: 8.09% active ingredient, 49.62% film-forming material, 27.59% disintegrant, 13.05% plasticizer and 1.65% other auxiliary ingredients.
4. The cariprazine hydrochloride orodispersible film preparation according to claim 1, It is characterized in that The cariprazine hydrochloride has a particle size range of D90=42μm-94μm.
5. The cariprazine hydrochloride orodispersible film preparation according to any one of claims 1 to 4, It is characterized in that The disintegrant is mannitol.
6. The cariprazine hydrochloride orodispersible film preparation according to any one of claims 1 to 4, It is characterized in that The other auxiliary ingredients include: flavoring agents, coloring agents and pH regulators.
7. A method for preparing the cariprazine hydrochloride orodispersible film preparation according to any one of claims 1 to 6, It is characterized in that When the film-forming material is a mixture of hydroxypropyl cellulose and hydroxypropyl methyl cellulose, the preparation method comprises the steps of: (1) dissolving hydroxypropyl cellulose in water at 80°C-100°C to obtain a hydroxypropyl cellulose solution; (2) stirring and dispersing the hydroxypropyl cellulose solution, active ingredient, disintegrant, plasticizer, hydroxypropyl methylcellulose, and other auxiliary ingredients to uniformly prepare a glue solution, coating, and drying to obtain a cariprazine hydrochloride orodispersible film preparation; When the film-forming material is polyethylene oxide, the preparation method comprises the steps of: dispersing and stirring the active ingredient, the film-forming material, the disintegrant, the plasticizer and other auxiliary ingredients in water to uniformly prepare a glue solution, coating and drying to obtain the cariprazine hydrochloride orodispersible film preparation.
